...doses of Hepagene, 8 lost their HBV DNA viremia. No serious side effects were reported. Medeva PLC...

...ordinary shares of PTE for £3.40 per share. Peptide Therapeutics Group plc (LSE:PTE), London, U.K. Medeva PLC...

...protection certificates (SPCs) before ruling in a suit related to SPC applications from Medeva BV. Medeva...
...EPO) 2009 rejection of its SPC applications for multivalent vaccines. EPO ruled that four of Medeva's...
...supporting patent identified both ingredients, the supporting marketing authorization covered a product with nine ingredients. Medeva...

...for head and neck cancerF. 4/20/98 - Raises $13.1M in PIPE G. 12/7/98 - Grants Medeva...

...data had begun to elicit interest from potential partners. In October 1998, the company granted Medeva plc...
...it was given back rights to tgAAVCF by Celltech Group plc , which had acquired Medeva...

...molecules, as it acquired these capabilities in its 1999 mergers with Chiroscience Group plc and Medeva plc...

...add to its London listing in January 2000 as a result of its merger with Medeva plc...

...to Medeva plc (Leatherhead, U.K.). Indeed, the Chiroscience acquisition was completed in August 1999 and the Medeva...
...announced in November (see BioCentury, Nov. 12, 1999). According to Fellner, the markets didn’t like Medeva’s...
...C. 11/11/99 - Medeva announcement; CCH 11/10/99 mkt cap = £732.9M ($1.2B) D. 1/26/00 - Medeva...

...CCH reached its current stage of development by merging with Chiroscience Group plc in 1999, Medeva...
...Thiemann Arzneimittel GmbH in 2001. This year CCH acquired Oxford GlycoSciences plc . While the Medeva...
...including a cough suppressant, a diuretic and treatments for ADHD. However, Ando argued that the Medeva...